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Key Clinical Message
Currently, there is no standard treatment for neurolymphomatosis because of
the scarcity of clinical studies. Here, we report the successful treatment of neu-
rolymphomatosis caused by follicular lymphoma with bendamustine, which
could be an effective treatment option for this condition.
Keywords
Bendamustine, blood-nerve barrier, follicular lymphoma, neurolymphomatosis.
Introduction
Neurolymphomatosis, the direct infiltration of lymphoma
cells into the peripheral or cranial nerves, occurs very rarely
in lymphoma patients [1]. It manifests chiefly in aggressive
B-cell or T-cell lymphomas and is not normally diagnosed
in patients with low-grade lymphomas such as follicular
lymphoma [2]. There is no standard treatment for neu-
rolymphomatosis because of the scarcity of clinical studies.
We report the successful treatment of neurolymphomatosis
caused by follicular lymphoma with bendamustine.
Case history
A 47-year-old woman with a history of follicular lym-
phoma presented with severe pain in her left leg. She had
been diagnosed with follicular lymphoma Grade I at age
30 years, and she had been assigned a low-risk classifica-
tion according to the follicular lymphoma international
prognostic index(FLIPI) score. Complete remission was
achieved after eight courses of the CHOP regimen
(cyclophosphamide, doxorubicin, vincristine, and pred-
nisolone). After the first complete remission, the patient
experienced multiple relapses, and she was treated with a
combination of chemotherapy and focal radiotherapy
(Table 1), achieving complete remission each time.
On admission, the patient had difficulty walking
because of the pain intensity. However, she did not report
sensory loss in either leg or the presence of symptoms of
bladder and bowel disturbances. Physical examination did
not reveal peripheral lymphadenopathy or hep-
atosplenomegaly. Findings of neurologic examination of
the cranial nerves were unremarkable. Upper and lower
limb examination did not show motor dysfunction or
sensory loss, and tendon reflexes were normal. Gadolin-
ium-enhanced magnetic resonance imaging (MRI)
revealed enlargement and strong postgadolinium enhance-
ment of the left sacral nerve root, findings consistent with
neurolymphomatosis (Fig. 1A). Positron emission tomog-
raphy did not show uptake around the sacral nerve root
or signs of lymphoma recurrence at other sites. Cytologi-
cal examination and flow cytometric analysis of cere-
brospinal fluid did not show any lymphoma infiltration.
Because of the difficulty in performing a biopsy of the
nerve, we diagnosed the patient with neurolymphomatosis
clinically, and initiated a BR regimen (90 mg/m2
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bendamustine on days 1 and 2 with 375 mg/m2 rituximab
on day 1). The pain began to resolve 4 days later and dis-
appeared completely by 2 weeks. MRI performed 3 weeks
after chemotherapy revealed shrinkage of the lesion. The
patient received six courses of BR, after which MRI
showed no sign of the lesion (Fig. 1B). No recurrence
was observed 14 months postchemotherapy.
Discussion
Systemic chemotherapy, including methotrexate, and
intrathecal chemotherapy as well as radiotherapy have tra-
ditionally been used for treating neurolymphomatosis.
However, their effectiveness is unclear because there are no
standardized criteria to measure treatment response [1].
Methotrexate, which penetrates the blood–brain and
blood–nerve barriers, can cause renal impairment and
mucositis, especially when administered in a high dose.
Bendamustine is effective for treating relapsed or refractory
indolent lymphoma [3]. However, there are no reports of
bendamustine penetrating the human blood–brain or
blood–nerve barriers, although another investigation
showed that bendamustine does cross the murine blood–
brain barrier [4]. Retrospective studies also showed the effi-
cacy of bendamustine for recurrent primary central nervous
system lymphoma [5, 6] and brain metastasis of breast can-
cer [7]. To the best of our knowledge, this is the first report
indicating that bendamustine can cross the human blood–
nerve barrier, and evidence suggests that bendamustine
may be effective not only for CNS lymphoma, but also for
neurolymphomatosis caused by follicular lymphoma.
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Table 1. Treatments provided from the onset of neurolymphomatosis.
Age Radiation Regimen Agent
Primary
lymphoma
30 CHOP Doxorubicin Cyclophosphamide Vincristine Prednisolone
1st relapse 32 40 Gy on
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MECP Mitoxantrone Etoposide Carboplatine Prednisolone
2nd relapse 40 R+mitoxantrone Rituximab Mitoxantrone
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Figure 1. Coronal images from gadolinium-enhanced magnetic resonance imaging at initial diagnosis of neurolymphomatosis (Panel A), and after
treatment with bendamustine (Panel B). Enlargement and strong postgadolinium enhancement of the left sacral nerve that was observed at
diagnosis (Panel A, arrow) disappeared after six courses of treatment with bendamustine and rituximab (Panel B, arrow).
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